Provided by Tiger Fintech (Singapore) Pte. Ltd.

TransCode Therapeutics Inc.

0.8148
+0.03484.46%
Pre-market: 0.7925-0.0223-2.74%08:26 EDT
Volume:1.76M
Turnover:1.39M
Market Cap:567.30K
PE:-0.01
High:0.8468
Open:0.8000
Low:0.7500
Close:0.7800
Loading ...

Transcode Therapeutics Announces First Patient Dosed in Third Cohort With Lead Candidate in Phase 1 Clinical Trial

THOMSON REUTERS
·
14 Jan

Transcode Therapeutics Inc - No Significant Safety or Dose Limiting Toxicities in Cohorts 1 and 2

THOMSON REUTERS
·
14 Jan

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

PR Newswire
·
14 Jan

BRIEF-Transcode Therapeutics Inc Nasdaq Determines Co Has Regained Compliance With Continued Listing Requirements

Reuters
·
07 Jan

Transcode Therapeutics regains Nasdaq compliance

TIPRANKS
·
07 Jan

Transcode Therapeutics Inc: Nasdaq Determines Co Has Regained Compliance With Continued Listing Requirements

THOMSON REUTERS
·
07 Jan

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

PR Newswire
·
07 Jan

Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), TransCode Therapeutics (RNAZ)

TIPRANKS
·
19 Dec 2024

Transcode Therapeutics Inc : H.c. Wainwright Adjusts Target Price to $20 From $3 After Reverse Stock Split

THOMSON REUTERS
·
19 Dec 2024

BRIEF-Transcode Therapeutics Announces Safety Review Committee Approval Of Opening Third Cohort And Preliminary Results From First Cohort In Phase 1 Ttx-Mc138 Trial

Reuters
·
18 Dec 2024

Transcode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results From First Cohort in Phase 1 Ttx-Mc138 Clinical Trial

THOMSON REUTERS
·
18 Dec 2024

Transcode Therapeutics Inc - No Significant Safety or Dose Limiting Toxicities Reported

THOMSON REUTERS
·
18 Dec 2024

Transcode Therapeutics Inc - Ttx-Mc138 Shows 66% Inhibition of Mir-10B at 24 Hours After Infusion

THOMSON REUTERS
·
18 Dec 2024

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

PR Newswire
·
18 Dec 2024

Transcode Therapeutics Inc trading halted, news pending

TIPRANKS
·
04 Dec 2024

BRIEF-Transcode Therapeutics Announces Effective Date For 1-For-33 Reverse Stock Split

Reuters
·
30 Nov 2024